ICON Public (NASDAQ:ICLR – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $15.00-$15.20 for the period, compared to the consensus EPS estimate of $15.07. The company issued revenue guidance of $8.45-$8.55 billion, compared to the consensus revenue estimate of $8.64 billion.
ICON Public Stock Performance
NASDAQ ICLR traded up $10.36 on Friday, hitting $323.46. 908,602 shares of the company’s stock were exchanged, compared to its average volume of 788,375. The firm has a market cap of $26.69 billion, a price-to-earnings ratio of 39.35, a P/E/G ratio of 1.40 and a beta of 1.23. The firm’s 50-day moving average price is $322.17 and its two-hundred day moving average price is $308.60. ICON Public has a fifty-two week low of $221.20 and a fifty-two week high of $347.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.21.
ICON Public (NASDAQ:ICLR – Get Free Report) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.75 earnings per share for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same quarter in the prior year, the company posted $2.96 earnings per share. ICON Public’s quarterly revenue was up 4.1% on a year-over-year basis. On average, research analysts expect that ICON Public will post 14.54 EPS for the current year.
Wall Street Analyst Weigh In
View Our Latest Research Report on ICLR
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
See Also
- Five stocks we like better than ICON Public
- Industrial Products Stocks Investing
- Why Call Options Volume for These 2 Stocks Spiked Together
- What is the NASDAQ Stock Exchange?
- MarketBeat Week in Review – 7/22 – 7/26
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.